Human papillomavirus type 16 (HPV-16) genotype variants have been the subject of several investigations, but study participants have rarely been sampled more than once. In this study, among a cohort of human immunodeficiency virus (HIV)-infected adults, HPV-16 variants were investigated in samples collected concurrently from the anus and cervix, as well as in serial samples collected from the same anatomical site at 12-month intervals. HPV-16 variants in stored extracts of cervical and anal samples were determined from subjects with multiple visits and at least one sample positive for HPV-16. Seven polymorphic nucleotide positions within the E6 region were analysed by pyrosequencing to determine genotype variants. Of 364 samples examined, 176 anal and 39 cervical swabs from 84 different subjects yielded unequivocal sequences of eight major HPV-16 variants. Eight samples contained probable novel HPV-16 variants and in one sample two variants were detected. In eight out of 29 (27.6 %) anal-cervical sample pairs positive for HPV-16, discordant variants were found. From 57 anal and nine cervical sample series of HPV-16-positive samples, a change in HPV-16 variant status over time was seen in nine (13.6 %) instances (seven anal and two cervical) from eight different participants. Changes in HPV-16 variants in HIV-infected adults were seen most frequently when different anatomical sites were sampled, but were also observed over time.
INTRODUCTION
Human papillomaviruses (HPVs) are classified on the basis of their genomic nucleic acid sequence, which is quite stable. According to papillomavirus taxonomy, a new HPV type must have .10 % sequence variation from other types, whilst smaller variations of 2-10 % and ,2 % dissimilarity are defined as subtypes and variants, respectively (de Villiers et al., 2004) . Numerous studies have analysed the frequency and distribution of HPV variants in different populations worldwide (Chopjitt et al., 2008; Tornesello et al., 2004; Yamada et al., 1995 Yamada et al., , 1997 . Four major HPV-16 variant groups have been identified on the basis of sequences in the long control region and the E5/E6 open reading frames (Chan et al., 1992; Ho et al., 1991 Ho et al., , 1993 . These variant groups are referred to as European (E), Asian (As), Asian-American (AA) and African (Af), loosely designating their geographical distribution.
HPV-16 variants are of considerable interest. Some studies have suggested that particular variants have a greater oncogenic potential for cervical cancer (Berumen et al., 2001; Chopjitt et al., 2008; Tornesello et al., 2004) , although other studies have found no association between HPV-16 variants and differential risk for cervical disease (Da Costa et al., 2002; Nindl et al., 1999; Rajeevan et al., 2005) . Variant analysis has also been proposed as means of assessing viral persistence (Londesborough et al., 1996) ; however, other results have not confirmed such a relationship (van Belkum et al., 1995) . Most studies of HPV variants have been cross-sectional and have usually analysed samples from a single anatomical location, either anal or cervical cells. Few studies have compared HPV-16 variant infections from two anatomical sites that were sampled concurrently or from the same anatomical location at different time points.
The objectives of this study were: (i) to describe HPV-16 variants in concurrently sampled anal and cervical specimens; and (ii) to assess changes longitudinally in HPV-16 variants from serially collected specimens at each of these anatomical sites in a cohort of HIV-infected adults.
RESULTS
We assayed 364 specimens (276 anal and 88 cervical) prepared from anal and cervical samples from the 40 women and 59 men with HPV-16 detected using a Linear Array (LA) HPV Genotyping Test (Roche Molecular Systems) in at least one sample: 203 were LA positive and 161 were LA negative for HPV-16. Pyrosequencing yielded 215 unequivocally positive results: 182/203 LApositive samples and 33/161 LA-negative samples. The mean number of HPV types other than HPV-16 was 4.4.
The 215 sequences were from 84 individual participants (31 women and 53 men) who provided 176 anal and 39 cervical samples: 29 pairs of concurrently collected anal and cervical samples from 18 women (six women provided pairs of concurrently collected anal-cervical specimens from multiple visits), 57 series of anal specimens collected sequentially at different study visits from 42 men and 15 women (nine pairs, 48 triplets) and nine sets of cervical specimens collected sequentially at different study visits (five pairs, four triplets).
Two hundred and seven (96.3%) sequences matched previously defined genotypes and were classified into HPV-16 variant lineages. As listed in Table 1 , the European variants E-G350 (35.8%) and Ep (33.5 %) were most frequently detected, followed by Af2 (10.7 %), Af1 (9.3 %), AA (2.3 %), EG131G (1.4 %), EC109G (1.4 %) and As (1.4 %). Eight samples (3.6 %) contained one of four previously undescribed HPV-16 variants (referred to as 'other'). Three of these novel variants were confirmed by the Sanger method and the E6 sequence fragments were submitted to GenBank; the remaining three samples did not produce unambiguous results by this method. At least one anal sample contained more than one variant.
Of the 29 pairs of concurrently collected anal and cervical samples from 18 women, eight pairs (27.6 %) from seven (38.9 %) women yielded discordant HPV-16 variants. The identity of the bases at the seven positions and the variant lineages are shown in Table 2 . One of the seven participants with discordant variants ( # 1052) contributed sets of samples from two visits.
Of the 66 series of sequentially collected anal and cervical samples from 59 participants, nine (13.6 %) series from eight (13.6 %) participants yielded discordant HPV-16 variants at different study visits; 12 changes were documented in total (Table 3) . One woman (#1052) showed HPV-16 variant differences in the series of both anal and cervical samples, as well as in two pairs of concurrently collected specimens from both anatomical sites (Tables 2 and 3 ).
DISCUSSION
Discordant variants were found in eight of the 29 sample pairs (27.7 %) in seven of 18 women (38.9 %). The HPV-16 variants detected at annual visits changed in nine (13.6 %) of the 66 series examined from eight (13.6 %) of 59 participants. Whilst a single HPV-16 variant was detected in most samples, clear evidence for a mixed infection with two variants was found in one sample (#1132).
We are aware of only one other study that has assessed infections with HPV-16 variants in concurrently collected anal and cervical specimens (van Belkum et al., 1995) . The investigators' genotype analysis in that study was based on Sanger sequencing of the E6 open reading frame and they reported no difference in the variants they identified in concurrently collected samples. The ability to sample both anatomical sites at multiple visits may have increased our ability to detect variant differences. Other studies that tested for variants longitudinally did not report changes in either cervical (Emeny et al., 1999; Tornesello et al., 2008) or anal (Xi et al., 1998) samples.
Our results illustrate the limitations in HPV typing and HPV variant detection to distinguish between persistent and recurrent infection. Failure to detect a type or specific variant at one time point or in one sample cannot be taken as evidence of clearance, as a negative HPV result is an imperfect indicator for the absence of infection. Similarly, detection of the same type or variant does not unambiguously indicate persistence, as new exposure to the same HPV genotype does not exclude reacquisition.
We found eight HPV-16 genotypes with base changes in the E6 region that have not been described previously. Two 
seven bases we analysed and other regions of the HPV-16 genome (Swan et al., 2006) , we believe that these eight sequences are very likely to represent novel variants.
Certain limitations of this study should be considered. As the survey was conducted in an HIV-positive cohort, it is not clear whether these results will be true for the general population. As the HIV cohort included participants with different degrees of immunocompromisation (e.g. CD4 cell counts ,200 cells ml 21 , not virologically suppressed), it will be important to determine how representative these data are of the general population. However, our results indicate that HPV detection at the type level to distinguish reinfection versus persistent infection should be interpreted with caution.
METHODS
Participants and sample collection. Specimens for this study were selected from samples of anal and cervical cells collected in the course of a prospective observational cohort study of HIV-infected adults in the USA (the SUN Study). Exfoliated anal cells were collected from all enrolled participants with a Dacron-tipped swab that was placed immediately in Digene specimen transport medium (STM; Qiagen). Exfoliated cervical cells were collected from all female participants. After visualization of the cervix during a pelvic examination, a Papette broom (Wallach Surgical Devices) was used to collect exfoliated ectoand endocervical cells. The broom was rinsed in 20 ml PreservCyt solution (Cytyc Corp.). Samples were collected by trained personnel at baseline, 12-month and 24-month study visits. All samples were stored at 4 uC and mailed weekly at ambient temperature to the Centers for Disease Control and Prevention where they were processed within 7 days of receipt. Between April 2004 and April 2007, 1750 samples were collected from 706 subjects. For our analysis of HPV-16 variants, we included all samples from the 99 subjects with more than one visit (40 women and 59 men) and in whom HPV-16 was detected in at least one sample.
DNA extraction and HPV typing. Anal samples were resuspended in STM and a 150 ml aliquot was added to 85 ml bacterial lysis buffer and 15 ml proteinase K solution from a MagNA Pure LC DNA Isolation kit III (Bacteria, Fungi) (Roche Diagnostics). After incubation for 1 h at 65 uC, DNA was extracted using the MagNA Pure LC system. The final eluate of 100 ml was stored at 220 uC until further use.
Cervical samples for the study were processed by centrifuging a 10 ml aliquot of the PreservCyt solution at 2000 g for 30 min to produce a cell pellet. The MasterPure Complete DNA and RNA Purification Method (Epicentre Technologies) was used with minor modifications to isolate total nucleic acids as described previously (Habis et al., 2004) . Briefly, cervical cells were lysed using 200 mg proteinase K per sample and a 50 min incubation at 60 uC, followed by further liquid phase separation and 2-propanol precipitation. The total nucleic acids were resuspended in 100 ml 10 mM Tris/HCl (pH 8.0)/1 mM EDTA and stored at 270 uC. For the HPV genotyping assay, a 1 : 6 dilution was prepared in nuclease-free water.
HPV genotypes were determined using a Linear Array HPV Genotyping Test (Roche Molecular Systems) designed to detect 37 individual HPV types (6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73, 81, 82, 83, 84, 89 and IS39) . Aliquots from anal (10 ml) and diluted cervical (5 ml) DNA extracts were PCR amplified in 100 ml volumes; otherwise the manufacturer's protocol was followed. Two technologists independently interpreted the HPV strips after a 1 h drying period.
Sequencing and variant determination. HPV-16 variants were determined in residual extracts using a pyrosequencing method as described previously (Swan et al., 2006) . In brief, sequencing templates were generated by PCR amplification of nt 75-388 in the E6 region. Successful amplification was verified by gel electrophoresis and a 20 ml aliquot of the amplicon was bound to streptavidin-coated Sepharose beads by agitation. After purification, the bead-bound single DNA strands were incubated at 80 uC together with sitespecific sequencing primers and analysed with a pyrosequencing PSQ 96MA apparatus (Biotage) according to the manufacturer's protocol. Polymorphisms at nt 109, 131, 132, 143, 145, 178 and 350 were determined in two separate pyrosequencing reactions using two separate sequencing primers for each sample. The region between nt 109 and 185 was resequenced with primer # 2 (59-AAAGAGAACTGCAATGTT-39, and nt 344-368 were analysed with primer # 6 (59-GTGAGTATAGACATTATTGT-39). If sequences showed clear signals for two different bases at the same position, both bases were recorded and both sequences were matched. Variants were finally classified as shown in Table 1 . For all samples with more than one variant or with differences in variant status between collection times or anatomical sites, PCR amplification and pyrosequencing were repeated and only recorded if the results were identical.
If the pyrosequencing signal intensity at specific polymorphic sites was not unequivocally above the background or noise level, sequencing was repeated with site-specific primers (Swan et al., 2006) . A subset of 14 samples was also subjected to the Sanger sequencing method. Thus, separate templates were generated by amplification of the E6/E7 region between nt 7740 and 943 as described previously .
